Drugs / WX-554
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01859351 | Jul 2013 → Apr 2014 | cancer | Heidelberg Pharma AG | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01581060 | Mar 2012 → Apr 2014 | cancer | Heidelberg Pharma AG | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WX-554 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859351 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3545145 ↗2“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3545145 ↗ “the MEK Inhibitor WX-554” NCT01581060 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3545145 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3545145 ↗ |